1,2-distearoyllecithin has been researched along with Local Neoplasm Recurrence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A | 1 |
| Chen, CA; Hsiao, SM; Hsieh, CY; Lin, HH; Wei, LH | 1 |
1 trial(s) available for 1,2-distearoyllecithin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols | 2009 |
1 other study(ies) available for 1,2-distearoyllecithin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |